(MedPage Today) — The effort by FDA Commissioner Marty Makary, MD, MPH, to drastically shorten the review of drugs favored by President Donald Trump’s administration is causing alarm across the agency, stoking worries that the plan may run afoul…
Source link : https://www.medpagetoday.com/publichealthpolicy/fdageneral/119467
Author :
Publish date : 2026-01-16 17:06:00
Copyright for syndicated content belongs to the linked Source.
